Presentation is loading. Please wait.

Presentation is loading. Please wait.

HEART TRANSPLANTATION Overall ISHLT 2011 ISHLT J Heart Lung Transplant. 2011 Oct; 30 (10): 1071-1132.

Similar presentations


Presentation on theme: "HEART TRANSPLANTATION Overall ISHLT 2011 ISHLT J Heart Lung Transplant. 2011 Oct; 30 (10): 1071-1132."— Presentation transcript:

1 HEART TRANSPLANTATION Overall ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

2 NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

3 NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

4 AVERAGE CENTER VOLUME Heart Transplants: January 1, 2003 – June 30, 2010 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

5 HEART TRANSPLANTS: Donor Age by Year of Transplant ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

6 AGE DISTRIBUTION OF HEART TRANSPLANT RECIPIENTS BY ERA ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

7 HEART TRANSPLANTATION Kaplan-Meier Survival (1/1982-6/2005) HEART TRANSPLANTATION Kaplan-Meier Survival (1/1982-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

8 HEART TRANSPLANTATION Adult Recipients ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

9 DIAGNOSIS IN ADULT HEART TRANSPLANTS ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

10 DIAGNOSIS IN ADULT HEART TRANSPLANTS Cardiomyopathy vs. CAD by Location ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

11 ADULT HEART TRANSPLANTS: DIAGNOSIS BY LOCATION Transplants between January 2005 and June 2010 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

12 (N=39,812 ) /2010 (N=27,387) p-value Recipient age (years) 54.0 ± 11.0 ( )54.0 ± 12.4 ( ) Donor age (years) 31.0 ± 12.8 ( )34.0 ± 13.1 ( )< Recipient/donor gender (% male) 80.5%/ 68.4%77.2%/ 69.5%<0.0001/ Recipient weight (kg) 75.0 ± 16.7 ( )78.0 ± 17.2 ( )< Recipient height (cm) ± 11.3 ( )175.0 ± 10.7 ( )< Recipient BMI 25.0 ± 4.3 ( )25.8 ± 4.7 ( )< Donor weight (kg) 75.0 ± 17.6 ( )*78.0 ± 17.1 ( )< Donor height (cm) ± 18.9 ( )*175.0 ± 10.3 ( )< Donor BMI 24.2 ± 4.5 ( )*25.2 ± 4.9 ( )< Recipient/donor diabetes mellitus 14.5%*/ 1.6%*22.7%/ 2.5%<0.0001/ < Recipient amiodarone use (US only) 22.6%*29.4%< Recipient/donor cigarette history -/ 37.5%*46.9%**/ 23.6%-/ < Recipient/donor hypertension 34.6%*/ 10.8%*40.9%/ 12.4%<0.0001/ < Recipient prior cardiac surgery -43.0%**- Continuous factors are expressed as median ± standard deviation (5 th -95 th percentiles) * Based on 4/ transplants. ** Based on 7/2004-6/2010 transplants. ADULT HEART TRANSPLANTATION Donor and Recipient Characteristics ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

13 (N=39,812 ) /2010 (N=27,387) p-value Recipient Peripheral Vascular Disease 3.9%*3.0%< Recipient previous malignancy3.5%*5.3%< Recipient COPD3.2%*3.6% Ischemic time (hours)2.6 ± 1.5 ( )3.0 ± 1.5 ( )< Most recent PRA > 10% Overall7.8%9.2%** Class I13.3%*** Class II9.0%*** Creatinine at time of transplant1.2 ± 9.7 ( )1.2 ± 0.9 ( ) Pulmonary vascular resistance (Wood units) 2.1 ± 2.2 ( )*2.1 ± 2.0 ( )< Continuous factors are expressed as median ± standard deviation (5th-95th percentiles) * Based on 4/ transplants. ** Based on US /2004 transplants and non US /2010 transplants *** Based on US 7/2004-6/2010 transplants. Until mid PRA was collected in US as a single percentage. After this date, PRA was collected separately for Class I and Class II. (Contd) ADULT HEART TRANSPLANTATION Donor and Recipient Characteristics ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

14 (N=39,812 ) /2010 (N=27,387) p-value HLA Mismatches %4.2% %40.4% %55.4% Diagnosis < Coronary artery disease45.7%39.5% Cardiomyopathy46.4%51.6% Valvular3.7%3.0% Retransplant1.9%2.4% Congenital1.9%2.8% Other causes0.4%0.7% ADULT HEART TRANSPLANTATION Donor and Recipient Characteristics (Contd) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

15 (N=39,812 ) /2010 (N=27,387) p-value Donor cause of death < Head trauma45.7%50.2% Stroke28.5%28.8% Other25.8%21.1% Pre-operative support (multiple items may be reported) Hospitalized at time of transplant58.7%46.0%< On IV inotropes55.3%*44.8%< LVAD1.7%***19.0%< IABP6.7% RVAD-4.1%****- Ventilator3.5%3.0% TAH0.1%***0.5%< ECMO0.3%**0.8%< (Contd) ADULT HEART TRANSPLANTATION Donor and Recipient Characteristics * Based on 4/ transplants. ** Based on 5/ transplants. *** Based on 11/ transplants. **** Based on /2010 transplants. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

16 ADULT HEART TRANSPLANTATION PRA DISTRIBUTION Transplants between July 2004 and June 2010 If Class I and Class II values were reported separately Class I PRA value was used ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

17 ADULT HEART TRANSPLANTATION % OF PATIENTS BRIDGED WITH MECHANICAL CIRCULATORY SUPPORT* (Transplants: 1/2000 – 12/2009) * LVAD, RVAD, TAH ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

18 ADULT HEART TRANSPLANTATION % OF PATIENTS BRIDGED WITH RVAD* (Transplants: 1/2005 – 12/2009) * RVAD, RVAD+LVAD ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

19 ADULT HEART TRANSPLANTATION Number of Combined Organ Transplants Reported By Year and Type of Transplant ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

20 ADULT HEART TRANSPLANTS DONOR AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2010 Mean/median donor age: Europe = 38.3/40.0 North America = 31.7/29.0 Other = 32.9/31.0 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

21 ADULT HEART TRANSPLANTS RECIPIENT AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2010 Mean/median recipient age: Europe = 50.1/53.0 North America = 51.8/55.0 Other = 48.3/51.0 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

22 ADULT HEART TRANSPLANTS RECIPIENT BMI DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2010 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

23 ADULT HEART TRANSPLANTS RECIPIENT DIABETES MELLITUS BY LOCATION Transplants between January 2000 and June 2010 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

24 ADULT HEART TRANSPLANTS RECIPIENT CIGARETTE HISTORY BY LOCATION Transplants between July 2004 and June 2010 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

25 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

26 ADULT HEART TRANSPLANTATION Conditional Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

27 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: 1/1982-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

28 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: 1/2002-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

29 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis (Transplants: 1/1982-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

30 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: 1/1982-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

31 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Cardiomyopathy ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

32 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Coronary Artery Disease ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

33 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Congenital ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

34 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Retransplant ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

35 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2009) Diagnosis: Valvular ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

36 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis (Transplants: 1/2002-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

37 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: 1/2002-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

38 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by PVR (Transplants: 1/2002-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

39 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Donor/Recipient Weight Ratio (Transplants: 1/2002-6/2009) For Recipients with PVR: 1- < 3 Wood units ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

40 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Donor/Recipient Weight Ratio (Transplants: 1/2002-6/2009) For Recipients with PVR: 3- < 5 Wood units ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

41 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Donor/Recipient Weight Ratio (Transplants: 1/2002-6/2009) For Recipients with PVR: 5+ Wood units ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

42 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 4/1994-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

43 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 1/2002-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

44 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 1/1999-6/2009) Conditional on Survival to 6 Months ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

45 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 7/2004-6/2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

46 ADULT HEART RE-TRANSPLANTS 1-Year Survival ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

47 ADULT HEART RECIPIENTS Cross-Sectional Analysis Functional Status of Surviving Recipients (Follow-ups: June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

48 ADULT HEART RECIPIENTS Functional Status of Surviving Recipients US Recipients Only (Follow-ups: March June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

49 ADULT HEART RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

50 ADULT HEART RECIPIENTS Employment Status of Surviving Recipients Age at Follow-up: Years (Follow-ups: June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

51 ADULT HEART RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

52 ADULT HEART RECIPIENTS Induction Immunosuppression (Transplants: January 2002 – June 2010) Analysis is limited to patients who were alive at the time of the discharge ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

53 ADULT HEART RECIPIENTS Induction Immunosuppression by Location Transplants: January 2002 – June 2010 Analysis is limited to patients who were alive at the time of the discharge ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

54 ADULT HEART RECIPIENTS Induction Immunosuppression (Transplants: 1997, 2002 and 1/2010-6/2010) Analysis is limited to patients who were alive at the time of the discharge Note: 3.3% of transplant recipients in 1/2010-6/2010 received Alemtuzumab ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

55 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Type (Transplants: 1/2000-6/2009, conditional on survival to 14 days) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

56 ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January June 2010) NOTE: Different patients are analyzed in Year 1 and Year 5 Analysis is limited to patients who were alive at the time of the follow-up ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

57 ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For the Same Patients (Follow-ups: January June 2010) Analysis is limited to patients who were alive at the time of the follow-up ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

58 ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of 1 Year Follow-up NOTE: Different patients are analyzed in each time frame. Analysis is limited to patients who were alive at the time of the follow-up ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

59 ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For the Same Patients (Follow-ups: January June 2010) Analysis is limited to patients who were alive at the time of the follow-up ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

60 ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January June 2010) NOTES: Different patients are analyzed in Year 1 and Year 5. In the Year 1 cohort 88.8% of patients were on prednisone; in the Year 5 cohort 54.0% of patients were on prednisone. Analysis is limited to patients who were alive at the time of the follow-up ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

61 ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up by Location (Follow-ups: January June 2010) NOTES: Different patients are analyzed in Year 1 and Year 5. Analysis is limited to patients who were alive at the time of the follow-up Year 1Year 5 ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

62 PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Type of Induction (Follow-ups: July 1, June 30, 2010) Overall FemaleMale No induction: N=4,744 Polyclonal: N=1,956 IL-2R antagonist: N=2,779 OKT3: N=187 All groups: all no induct vs. poly and no induct vs. IL-2R comparisons are significant at p < 0.05 except 45-62: no induct vs. poly and M: no induct vs. poly Overall: no induct vs. OKT3 (p=0.0120); poly vs. IL-2R (p=0.0019) 45-62: poly vs. IL-2R (p=0.0280) 63+: no induct vs. OKT3 (p=0.0093) M: poly vs. IL-2R (p=0.0014) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

63 PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS Experiencing Rejection between Transplant Discharge and 1-Year Follow-Up Stratified by Maintenance Immunosuppression (Follow-ups: July 1, June 30, 2010) Overall: p < : p < : p < : p = Female: p < Male: p < NOTE: There were 163 patients with cyclosporine + AZA and 57 with tacrolimus+AZA. These groups were excluded due to small numbers. Cyclosporine + MMF/MPA: N = 3,113 Tacrolimus + MMF/MPA: N = 5, MaleFemaleOverall Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

64 ADULT HEART TRANSPLANTATION Kaplan-Meier Survival Stratified by Treatment for Rejection Within 1 st Year Conditional on survival to 1 year (1 Year follow-ups: 7/2004-6/2009) Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti-rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

65 FREEDOM FROM HOSPITALIZATION FOR REJECTION BY ERA For Adult Heart Recipients (Transplants: April 1994-June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

66 POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post- Transplant (Follow-ups: April June 2010) Outcome Within 1 Year Total N with known response Within 5 Years Total N with known response Within 10 Years Total N with known response Hypertension*72.9%(N = 25,435)92.9%(N = 11,156)- Renal Dysfunction26.6%(N = 26,918)30.3%(N = 13,239)36.0%(N = 4,274) Abnormal Creatinine < 2.5 mg/dl18.1%20.5%24.4% Creatinine > 2.5 mg/dl6.7%7.0%5.3% Chronic Dialysis1.5%2.3%4.8% Renal Transplant0.3%0.4%1.5% Hyperlipidemia*58.2%(N = 26,773)87.9%(N = 12,483)- Diabetes*26.9%(N = 26,913)37.4%(N = 12,195)- Cardiac Allograft Vasculopathy7.8%(N = 24,361)30.6%(N = 8,988)51.1%(N = 2,137) * Data are not available 10 years post transplant ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

67 Outcome Within 1 Year Total N with known response Within 5 Years Total N with known response Within 10 Years Total N with known response Renal Dysfunction18.7%(N = 1,852)26.9%(N = 1,852)34.0%(N = 1,852) Abnormal Creatinine < 2.5 mg/dl12.6%21.2%25.0% Creatinine > 2.5 mg/dl5.9%4.6%4.0% Chronic Dialysis0.1%0.7%3.5% Renal Transplant0.2%0.4%1.5% Cardiac Allograft Vasculopathy7.2%(N = 1,852)30.2%(N = 1,852)50.9%(N = 1,852) POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post- Transplant (Transplants: June 2000) For the Same Patients ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

68 Outcome Within 1 Year Total N with known response Within 5 Years Total N with known response Hypertension75.1%(N = 3,273)89.5%(N = 3,273) Renal Dysfunction26.3%(N = 3,273)28.9%(N = 3,273) Abnormal Creatinine < 2.5 mg/dl20.7%22.1% Creatinine > 2.5 mg/dl4.8%5.0% Chronic Dialysis0.5%1.5% Renal Transplant0.3% Hyperlipidemia73.4%(N = 3,273)90.7%(N = 3,273) Diabetes28.0%(N = 3,273)40.0%(N = 3,273) Cardiac Allograft Vasculopathy5.4%(N = 3,273)27.1%(N = 3,273) POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 and 5 Years Post-Transplant (Transplants: June 2005) For the Same Patients ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

69 FREEDOM FROM CARDIAC ALLOGRAFT VASCULOPATHY For Adult Heart Recipients (Transplants: April 1994-June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

70 FREEDOM FROM SEVERE RENAL DYSFUNCTION BY ERA* For Adult Heart Recipients (Transplants: April 1994-June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

71 PATIENT SURVIVAL AFTER REPORT OF CAV WITHIN 3 YEARS OF TRANSPLANT AND PATIENT SURVIVAL IN PATIENTS WITHOUT CAV* (Transplants: April 1994-June 2009) * Survival for patients without CAV within 3 years after transplant was conditioned on survival to median time of CAV development (509 days). Median time to CAV development is based on patients who developed CAV within 3 years of transplant. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

72 PATIENT SURVIVAL AFTER REPORT OF CAV WITHIN 3 YEARS OF TRANSPLANT AND PATIENT SURVIVAL IN PATIENTS WITHOUT CAV* BY ERA (Transplants: April 1994-June 2009) ISHLT 2011 * Survival for patients without CAV within 3 years after transplant was conditioned on survival to median time of CAV development (509 days). Median time to CAV development is based on patients who developed CAV within 3 years of transplant. ISHLT J Heart Lung Transplant Oct; 30 (10):

73 MALIGNANCY POST-HEART TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April June 2010) Malignancy/Type1-Year Survivors 5-Year Survivors 10-Year Survivors No Malignancy27,316 (97.3%)11,751 (85.9%)3,122 (71.3%) Malignancy (all types combined)764 (2.7%)1,933 (14.1%)1,256 (28.7%) Malignancy Type Skin3731, Lymph Other Type Not Reported Other includes: prostate (11, 35, 21), adenocarcinoma (7, 7, 4), lung (6, 4, 1), bladder (4, 5, 4), Kaposi's sarcoma (0, 3, 1), breast (2, 7, 2), cervical (2, 5, 2), colon (2, 4, 2), and renal (2, 7, 2). Numbers in parentheses are those reported within 1 year, 5 years and 10 years, respectively. NOTE: Multiple types may be reported; sum of types may be greater than total number with malignancy. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

74 FREEDOM FROM MALIGNANCY For Adult Heart Recipients (Follow-ups: April June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

75 FREEDOM FROM MALIGNANCY by Maintenance Immunosuppression Combinations at Discharge For Adult Heart Recipients (Transplants: January June 2009) Conditional on Survival to 14 days ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

76 FREEDOM FROM MALIGNANCY For Adult Heart Recipients (Transplants : April June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

77 FREEDOM FROM SKIN MALIGNANCY For Adult Heart Recipients (Transplants : April June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

78 FREEDOM FROM SKIN MALIGNANCY by Location For Adult Heart Recipients (Follow-ups: April June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

79 FREEDOM FROM LYMPHOMA For Adult Heart Recipients (Transplants : April June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

80 FREEDOM FROM LYMPHOMA by Age Group For Adult Heart Recipients (Follow-ups: April June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

81 FREEDOM FROM OTHER MALIGNANCY For Adult Heart Recipients (Transplants : April June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

82 ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January June 2010) CAUSE OF DEATH 0-30 Days (N = 4,094) 31 Days – 1 Year (N = 4,028) >1 Year – 3 Years (N = 3,166) >3 Years – 5 Years (N = 2,674) >5 Years – 10 Years (N = 6,273) >10 Years – 15 Years (N =3,616) >15 Years (N =1,753) Cardiac Allograft Vasculopathy 78 (1.9%)195 (4.8%)458 (14.5%)428 (16.0%)944 (15.0%)521 (14.4%)232 (13.2%) Acute Rejection 256 (6.3%)474 (11.8%)323 (10.2%)122 (4.6%)116 (1.8%)36 (1.0%)31 (1.8%) Lymphoma 3 (0.1%)76 (1.9%)110 (3.5%)110 (4.1%)271 (4.3%)146 (4.0%)61 (3.5%) Malignancy, Other 3 (0.1%)106 (2.6%)360 (11.4%)489 (18.3%)1,202 (19.2%)723 (20.0%)293 (16.7%) CMV 4 (0.1%)45 (1.1%)18 (0.6%)5 (0.2%)6 (0.1%)1 (0.0%)4 (0.2%) Infection, Non-CMV 539 (13.2%)1,203 (29.9%)392 (12.4%)268 (10.0%)684 (10.9%)373 (10.3%)260 (14.8%) Graft Failure 1,643 (40.1%)723 (17.9%)732 (23.1%)544 (20.3%)1,112 (17.7%)582 (16.1%)246 (14.0%) Technical 300 (7.3%)54 (1.3%)36 (1.1%)27 (1.0%)59 (0.9%)39 (1.1%)38 (2.2%) Other 201 (4.9%)312 (7.7%)289 (9.1%)208 (7.8%)535 (8.5%)296 (8.2%)157 (9.0%) Multiple Organ Failure 591 (14.4%)460 (11.4%)152 (4.8%)150 (5.6%)441 (7.0%)289 (8.0%)144 (8.2%) Renal Failure 24 (0.6%)41 (1.0%)55 (1.7%)95 (3.6%)371 (5.9%)298 (8.2%)133 (7.6%) Pulmonary 164 (4.0%)160 (4.0%)123 (3.9%)126 (4.7%)257 (4.1%)150 (4.1%)77 (4.4%) Cerebrovascular 288 (7.0%)179 (4.4%)118 (3.7%)102 (3.8%)275 (4.4%)162 (4.5%)77 (4.4%) Percentages represent % of deaths in the respective time period ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

83 ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death from Leading Causes by Time since Transplant and Era (Deaths: January June 2010) Deaths 1998 – June 2010Deaths ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

84 ADULT HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

85 ADULT HEART TRANSPLANT RECIPIENTS: Cumulative Incidence of Leading Causes of Death (Transplants: January June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

86 ADULT HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2010) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

87 ADULT HEART TRANSPLANT RECIPIENTS: Cumulative Incidence of Leading Causes of Death (Transplants: January June 2009) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

88 ADULT HEART TRANSPLANTS (1/2004-6/2009) Risk Factors for 1 Year Mortality (N=10,271) * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

89 ADULT HEART TRANSPLANTS (1/2004-6/2009) Borderline Significant Risk Factors for 1 Year Mortality (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

90 ADULT HEART TRANSPLANTS (1/2004-6/2009) Risk Factors for 1 Year Mortality ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

91 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

92 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

93 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height (N=10,271) ISHLT 2011 * The risk associated with recipient height should be considered in conjunction with the risk associated with recipient weight and donor weight. ISHLT J Heart Lung Transplant Oct; 30 (10):

94 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Weight (N=10,271) ISHLT 2011 * The risk associated with recipient weight should be considered in conjunction with the risk associated with recipient height and donor weight. ISHLT J Heart Lung Transplant Oct; 30 (10):

95 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Weight (N=10,271) ISHLT 2011 * The risk associated with donor weight should be considered in conjunction with the risk associated with recipient height and recipient weight. ISHLT J Heart Lung Transplant Oct; 30 (10):

96 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

97 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Center Volume (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

98 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

99 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

100 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits PRA Class II (%) (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

101 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pulmonary Capillary Wedge Pressure (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

102 ADULT HEART TRANSPLANTS (1/2004-6/2009) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PVR (N=10,271) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

103 ADULT HEART TRANSPLANTS (1/2004-6/2009) Factors Not Significant for 1 Year Mortality Recipient Factors: Prior malignancy, hospitalized, prior pregnancy, balloon pump, diabetes, gender Donor Factors: Clinical infection, history of diabetes, gender, history of hypertension, cause of death, history of malignancy Transplant Factors: HLA mismatch, CMV mismatch, prior transplant ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

104 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Risk Factors for 1 Year Mortality (N=958) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

105 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Borderline Significant Risk Factors for 1 Year Mortality (N=958) ISHLT 2011 * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. There were too few temporary continuous flow devices to analyze. ISHLT J Heart Lung Transplant Oct; 30 (10):

106 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Risk Factors for 1 Year Mortality ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

107 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age (N=958) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

108 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=958) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

109 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=958) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

110 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits PRA Class I (%) (N=958) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

111 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PA Systolic Pressure (N=958) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

112 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Risk Factors for 1 Year Mortality (N=6,583) ISHLT 2011 * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. ISHLT J Heart Lung Transplant Oct; 30 (10):

113 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Borderline Significant Risk Factors for 1 Year Mortality (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

114 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Risk Factors for 1 Year Mortality ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

115 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

116 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

117 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height (N=6,583) ISHLT 2011 * The risk associated with recipient height should be considered in conjunction with the risk associated with recipient weight and BMI ratio. ISHLT J Heart Lung Transplant Oct; 30 (10):

118 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Weight (N=6,583) ISHLT 2011 * The risk associated with recipient weight should be considered in conjunction with the risk associated with recipient height and BMI ratio. ISHLT J Heart Lung Transplant Oct; 30 (10):

119 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor BMI (N=6,583) ISHLT 2011 * The risk associated with donor BMI should be considered in conjunction with the risk associated with BMI ratio. ISHLT J Heart Lung Transplant Oct; 30 (10):

120 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

121 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

122 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

123 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits PRA Class I (%) (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

124 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PA Diastolic Pressure (N=6,583) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

125 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Risk Factors for 1 Year Mortality (N=2,721) ISHLT 2011 * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. There were too few temporary continuous flow devices to analyze. ISHLT J Heart Lung Transplant Oct; 30 (10):

126 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Risk Factors for 1 Year Mortality ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

127 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=2,721) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

128 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height (N=2,721) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

129 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time (N=2,721) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

130 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=2,721) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

131 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin (N=2,721) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

132 ADULT HEART TRANSPLANTS (1/2004-6/2009) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits TPG (N=2,721) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

133 ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality (N=10,785) ISHLT 2011 * Temporary circulatory support includes ECMO and temporary pulsatile flow devices. There were too few temporary continuous flow devices to analyze. ISHLT J Heart Lung Transplant Oct; 30 (10):

134 ADULT HEART TRANSPLANTS (1/2000-6/2005) Borderline Significant Risk Factors for 5 Year Mortality (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

135 ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

136 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Age (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

137 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Height (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

138 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Donor Age (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

139 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Donor and Recipient BMI Difference (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

140 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Bilirubin (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

141 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits TPG (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

142 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Ischemia Time (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

143 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

144 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Center Volume (N=10,785) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

145 ADULT HEART TRANSPLANTS (1/2000-6/2005) Factors Not Significant for 5 Year Mortality Recipient Factors: Sternotomy, pulmonary embolism, IV inotropes, prior malignancy, balloon pump Donor Factors: History of cancer, clinical infection, cause of death, history of hypertension Transplant Factors: CMV mismatch, ABO match, previous transplant ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

146 ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

147 ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (contd) (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

148 ADULT HEART TRANSPLANTS (1/2000-6/2005) Borderline Significant Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

149 ADULT HEART TRANSPLANTS (1/2000-6/2005) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

150 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Recipient Age (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

151 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Recipient BMI (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

152 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Donor Age (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

153 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year PVR (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

154 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Center Volume (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

155 ADULT HEART TRANSPLANTS (1/2000-6/2005) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Pre-Transplant Recipient Serum Creatinine (N=9,189) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

156 ADULT HEART TRANSPLANTS (1995-6/2000) Risk Factors for 10 Year Mortality (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

157 ADULT HEART TRANSPLANTS (1995-6/2000) Borderline Significant Risk Factors for 10 Year Mortality (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

158 ADULT HEART TRANSPLANTS (1995-6/2000) Risk Factors for 10 Year Mortality (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

159 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Age (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

160 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Donor Age (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

161 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Pre-Transplant Recipient Weight (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

162 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Pre-Transplant Recipient Height (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

163 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Ischemia Time (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

164 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

165 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Bilirubin (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

166 ADULT HEART TRANSPLANTS (1995-6/2000) Relative Risk of 10 Year Mortality with 95% Confidence Limits Center Volume (N=11,861) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

167 ADULT HEART TRANSPLANTS (1/1990-6/1995) Risk Factors for 15 Year Mortality (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

168 ADULT HEART TRANSPLANTS (1/1990-6/1995) Borderline Significant Risk Factors for 15 Year Mortality (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

169 ADULT HEART TRANSPLANTS Risk Factors for 15 Year Mortality (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

170 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Age (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

171 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Donor Age (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

172 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Height (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

173 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Weight (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

174 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

175 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Ischemia Time (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

176 ADULT HEART TRANSPLANTS (1/1990-6/1995) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant PRA (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

177 ADULT HEART TRANSPLANTS (1/1985-6/1990) Risk Factors for 20 Year Mortality (N=13,578) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

178 ADULT HEART TRANSPLANTS Risk Factors for 20 Year Mortality (N=13,578) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

179 ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Recipient Age (N=13,578) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

180 ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Donor Age (N=13,578) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

181 ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Ischemia Time (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

182 ADULT HEART TRANSPLANTS (1/1985-6/1990) Relative Risk of 20 Year Mortality with 95% Confidence Limits Center Volume (N=10,342) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

183 ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

184 ADULT HEART TRANSPLANTS (1/2003-6/2009) Borderline Significant Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

185 ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction Pre-Transplant Conditional on Survival to Transplant Discharge (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

186 ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient Age (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

187 ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient Pre-Transplant Creatinine (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

188 ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient Pre-Transplant Weight (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

189 ADULT HEART TRANSPLANTS (1/2003-6/2009) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Conditional on Survival to Transplant Discharge Recipient PA Systolic Pressure (N=9,916) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

190 ADULT HEART TRANSPLANTS (1/1998-6/2002) Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge (N=6,264) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

191 ADULT HEART TRANSPLANTS (1/1998-6/2002) Borderline Significant Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge (N=6,264) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

192 (N=6,264) ADULT HEART TRANSPLANTS (1/1998-6/2002) Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

193 ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Recipient Age (N=6,264) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

194 ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Donor BSA (N=6,264) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

195 ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Donor Age (N=6,264) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

196 ADULT HEART TRANSPLANTS (1/1998-6/2002) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Center Volume (N=6,264) ISHLT 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):


Download ppt "HEART TRANSPLANTATION Overall ISHLT 2011 ISHLT J Heart Lung Transplant. 2011 Oct; 30 (10): 1071-1132."

Similar presentations


Ads by Google